Buscas alternativas:
decrease processes » disease processes (Expandir a busca), decay processes (Expandir a busca), increase process (Expandir a busca)
decrease decrease » decrease release (Expandir a busca), disease decreases (Expandir a busca), decreases disease (Expandir a busca)
decrease docking » decrease during (Expandir a busca), decrease owing (Expandir a busca), decrease lodging (Expandir a busca)
docking receptor » sensing receptor (Expandir a busca), docking center (Expandir a busca)
decrease toc » decrease of (Expandir a busca), decrease the (Expandir a busca), decrease on (Expandir a busca)
toc decrease » to decrease (Expandir a busca), the decrease (Expandir a busca), not decrease (Expandir a busca)
decrease and » decreases and (Expandir a busca), decrease in (Expandir a busca), decrease of (Expandir a busca)
and decrease » and decreases (Expandir a busca), and decreased (Expandir a busca), and increase (Expandir a busca)
decrease processes » disease processes (Expandir a busca), decay processes (Expandir a busca), increase process (Expandir a busca)
decrease decrease » decrease release (Expandir a busca), disease decreases (Expandir a busca), decreases disease (Expandir a busca)
decrease docking » decrease during (Expandir a busca), decrease owing (Expandir a busca), decrease lodging (Expandir a busca)
docking receptor » sensing receptor (Expandir a busca), docking center (Expandir a busca)
decrease toc » decrease of (Expandir a busca), decrease the (Expandir a busca), decrease on (Expandir a busca)
toc decrease » to decrease (Expandir a busca), the decrease (Expandir a busca), not decrease (Expandir a busca)
decrease and » decreases and (Expandir a busca), decrease in (Expandir a busca), decrease of (Expandir a busca)
and decrease » and decreases (Expandir a busca), and decreased (Expandir a busca), and increase (Expandir a busca)
1
2
3
4
5
6
“... receptor 2 (VEGFR2) inhibition activity. Here, we present the synthesis of new 1-aryl-3-[4-(thieno...”
Acessar documento
Acessar documento
7
8
“...Os inibidores do receptor de angiotensina II do tipo 1 (AT1R), fármacos da classe das sartanas...”
Acessar documento
Acessar documento
Dissertação
9
10
11
12
“... genômico da CPB2.8, nos permite utilizar estratégias de planejamento de fármacos baseado no receptor (SBDD...”
Acessar documento
Acessar documento
Tese
13
14
15
16
Assuntos:
“...DFT, Molecular Docking, Cyclodextrin, GROMOS, Central Nervous System...”
Acessar documento
Acessar documento
Tese
17
Assuntos:
“...DFT, Molecular Docking, Cyclodextrin, GROMOS, Central Nervous System...”
Acessar documento
Acessar documento
Tese
18
Assuntos:
“...DFT, Molecular Docking, Cyclodextrin, GROMOS, Central Nervous System...”
Acessar documento
Acessar documento
Tese
19
20